REVENUEFLOOR
Paid pilot, for a revenue cycle director in Saudi Arabia

Thirty days on one hold queue. A price you can approve without a committee.

One repeat billing hold or edit queue. One facility. Weekly reports with an owner and a decision date on every line. A measurement contract using your own numbers, never ours.

Request the pilotRead the scope USD 2,500 once. One queue. One facility. Thirty days.
  1. 01 / ScopeAgree the queue, facility, and measurement inputs.
  2. 02 / Pay onceUse the fixed USD 2,500 pilot price.
  3. 03 / ReviewReceive a weekly worklist and a final report.
Revenue cycle work delivered at

The founder's own work history, not a NOMOI customer, reference, or pilot partner.

Sheikh Shakhbout Medical City Sheikh Khalifa Medical City, part of SEHA Ahalia Medical Group
Scope

What the thirty days covers

Synthetic proof only. See revenuefloor.com for the worked example. No hospital results are claimed here.

Queue and facility

  • One hold or edit queue class, picked with you from what your own systems already produce.
  • One facility. Thirty calendar days.

Data in

  • A dated extract you already run, de-identified before it reaches NOMOI. Stable keys, hold or edit kind, reason code, report dates. No names, no MRN, no free text patient notes.
  • Or a read-only connector against your own reporting view, same rule: de-identified before NOMOI reads it.

Where NOMOI stops

  • No clinical data. No patient identity. No write access to your billing or clinical systems.
  • NOMOI reviews and reports. Your team decides and acts on your own systems.

Geography

  • Saudi Arabia first, then Bahrain, Kuwait, Oman, Qatar. Never the UAE.
  • No SSMC reference, case study, or lead, at any point.
Weekly deliverables

What lands in your inbox each week

Week 1Scope confirmed in writing. Baseline queue pulled and mapped to stable keys. First count: total lines, distinct keys, repeat appearances from before day one.
Week 2Worklist with an owner and a review status on every line. First read on hold or edit reason distribution: recurring versus one-time.
Week 3Current billing-system state checked against the worklist for every line still open. Report on what changed since week one.
Week 4Final report. Completed review rate, decision date coverage, reason breakdown, and the measurement contract result, only where you have supplied the inputs it needs.
The success formula

The measurement contract

Money is not assumed. It is computed only from what you supply: staffed bed count, currency, an intervention cost figure, and a matched before and after cash window for the reviewed queue.

100 * (incremental collections minus incremental cost) / (staffed beds * observation months)

Cash that arrived sooner but was not new money is reported separately and never folded into this formula. Without your inputs, the report stops at reviewed, actioned, and current billing state, with no dollar or riyal figure attached.

Price

USD 2,500, one time, for the thirty day pilot.

$0 One time · one queue class · one facility · thirty days

This price sits below most hospital director-level spending thresholds, so you do not need to escalate the purchase to approve it. It covers roughly twenty to thirty hours of weekly review and reporting across the four weeks. It buys the review. It does not buy a claim of recovered revenue: that is only reported once your own staffed-bed, currency, cost, and cash-window numbers are behind it.

Request the pilot

Kill criterion

Where NOMOI stops on its own

If, by day thirty, NOMOI has not produced a completed first-review status (cleared, still held with a named reason, or escalated) on at least eighty percent of the queue lines in scope, the pilot ends there. NOMOI delivers the partial worklist and the review-rate report, states plainly that the pilot did not reach its own bar, and does not propose a renewal or a second pilot on the same queue class. No invoice is raised beyond the one-time price already paid.

What NOMOI never touches

On every pilot, without exception

  • Never sells, stores beyond the pilot term, or transfers patient data. Only de-identified extracts or a read-only connector view, only for the agreed scope.
  • Never sells or markets to a UAE buyer. Saudi Arabia first, then the rest of the GCC, then the world.
  • Never claims a recovered-revenue figure without your own staffed-bed, currency, cost, and cash-window inputs behind it.
  • Never writes to your billing or clinical systems. Review and report only.

NOMOI sells the systems it builds, never your data. See how the review works and the synthetic proof on the main page.